AOD-9604 + CJC-1295 + Ipamorelin (12mg)
A blend of three peptides: AOD-9604 (4 mg, GH fragment 176-191 for lipolysis), CJC-1295 (4 mg, GHRH analog for GH increase), and Ipamorelin (4 mg, selective ghrelin agonist). The combination aims for a triple synergistic action: lipolysis, prolonged GHRH signaling, and selective GH secretion without increasing cortisol. Administered subcutaneously once daily.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment (amino acids 176-191) of human growth hormone that activates lipolysis without the anabolic or diabetogenic effects of full GH. It acts by activating β3-adrenergic receptors in adipose tissue. CJC-1295 is a modified GHRH(1-29) analog that provides prolonged GHRH signaling, increasing endogenous GH and IGF-1 for 6–8 days. Ipamorelin is a pentapeptide that binds to the ghrelin receptor (GHS-R1a), selectively stimulating GH without increasing ACTH or cortisol. The triple combination provides enhanced lipolysis, increased muscle protein synthesis, and improved body composition.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → 4 mg/mL total (~1.33 mg/mL per component).
- Typical Daily Range: 100–300 mcg per component (300–900 mcg total) with gradual titration.
- Storage: Lyophilized: freezer at −20 °C · after reconstitution: refrigerator at 2–8 °C · use within 3–4 weeks.
12-Week Gradual Titration (3 mL = 4 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 100 mcg/component (300 mcg total) | 2.5 Units (0.03 mL) |
| Weeks 3–4 | 200 mcg/component (600 mcg total) | 5 Units (0.05 mL) |
| Weeks 5–12 | 300 mcg/component (900 mcg total) | 7.5 Units (0.07 mL) |
Studies report administration once daily subcutaneously, preferably at bedtime on an empty stomach (2+ hours after the last meal). This timing enhances nocturnal GH secretion and maximizes lipolytic action.
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water with a sterile syringe (ideally a 3 mL syringe with a 21–23 gauge needle).
- Inject slowly down the side of the vial; avoid foaming (do not spray directly onto the powder).
- Gently swirl or rotate until fully dissolved (do not shake vigorously).
- Note the reconstitution date and concentration (4 mg/mL); refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Goal: Synergistic fat loss and GH enhancement via triple action: lipolysis (AOD-9604) + GHRH (CJC-1295) + GHS (Ipamorelin).
- Schedule: Daily subcutaneous injections for 8–12 weeks, followed by a 4-week washout period.
- Storage: Lyophilized frozen · reconstituted refrigerated · use within 3–4 weeks.
Dosing Protocol
- Initiation: 100 mcg per component daily (7.5 units) to assess tolerance.
- Increase: 200 mcg per component (15 units) during weeks 3–4.
- Target: 300 mcg per component (22.5 units) during weeks 5–12.
- Timing: At bedtime on an empty stomach (2+ hours post-meal) for maximal GH response.
- Cycle Duration: 8–12 weeks on, 4 weeks off.
- Break between cycles: After the cycle, a 4–6 week washout period is recommended. The triple combination (AOD + CJC + Ipamorelin) acts on multiple pathways — the pause prevents tolerance buildup.
Washout & Cycle Restart
When can I restart?
After the cycle, a 4–6 week washout period is recommended. The triple combination (AOD + CJC + Ipamorelin) acts on multiple pathways — the pause prevents tolerance buildup.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C; use within 3–4 weeks.
- Allow frozen vials to reach room temperature before opening.
Important Notes
- Inject on an empty stomach (2+ hours post-meal) — carbohydrate intake reduces GH response.
- Aseptic technique: clean the vial stopper and skin with separate alcohol pads.
Potential Benefits & Side Effects
Potential Benefits:
- Enhanced lipolysis and loss of visceral/subcutaneous fat through triple action.
- Increased GH/IGF-1 levels without an increase in cortisol (selectivity of Ipamorelin).
- Improved body composition — muscle mass ↑, body fat ↓.
- Supports recovery, sleep quality, and skin elasticity.
- Well-tolerated in clinical studies.
Potential Side Effects:
- Mild injection site reaction (redness, itching).
- Transient increase in appetite due to ghrelin action (Ipamorelin/CJC).
- Slight dizziness at high doses (rare).
- Water retention (especially initially) — usually transient.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical risk (GH/IGF-1 elevation)
As a GHS, increases GH. Theoretical risk for pre-existing neoplasms due to IGF-1 elevation. No clinical signal in short-term studies.
📄 Growth Horm IGF Res 2008Failed clinical trials — questionable efficacy
The Phase III obesity trial did not meet primary endpoint. Long-term safety as injectable has not been documented (GRAS only for oral use).
📄 Metabolic Pharmaceuticals (Clinical Trial Data)References
- Obesity Research — AOD-9604: lipolytic action without anabolic GH effects
View Source - J Clin Endocrinol Metab — CJC-1295: prolonged increase in GH/IGF-1 for 6–8 days
View Source - Eur J Endocrinol — Ipamorelin: the first selective GH secretagogue without ACTH/cortisol effects
View Source - Endocrine Reviews — GH secretagogues: mechanisms & clinical applications
View Source - Transl Androl Urol (PMC) — GH secretagogues in improving body composition
View Source
External Sources & Regulatory Status
Regulatory Approvals
GRAS (oral) — Not approved as an injectable
FDA GRAS (oral only)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →